Effect of home-based cardiac rehabilitation on quality of life, health behaviours and cardiac anxiety in patients with coronary artery disease: findings from a single-blinded randomised controlled trial.
A, Y., L, L., AH, K., A, A., A, H., FY, P., F, K., W, S., & R, B. (2026). Effect of home-based cardiac rehabilitation on quality of life, health behaviours and cardiac anxiety in patients with coronary artery disease: findings from a single-blinded randomised controlled trial.. BMJ open. https://doi.org/10.1136/bmjopen-2025-114349
A Y, L L, AH K, A A, A H, FY P, et al. Effect of home-based cardiac rehabilitation on quality of life, health behaviours and cardiac anxiety in patients with coronary artery disease: findings from a single-blinded randomised controlled trial.. BMJ open. 2026; doi: 10.1136/bmjopen-2025-114349
A Y, L L, AH K, et al. Effect of home-based cardiac rehabilitation on quality of life, health behaviours and cardiac anxiety in patients with coronary artery disease: findings from a single-blinded randomised controlled trial.[J]. BMJ open. 2026. DOI: 10.1136/bmjopen-2025-114349.
@article{a2026,
author = {Yaqoob A and Ladak L and Khan AH and Almas A and Hanif A and Pannu FY and Khemani F and Sahar W and Barolia R},
title = {Effect of home-based cardiac rehabilitation on quality of life, health behaviours and cardiac anxiety in patients with coronary artery disease: findings from a single-blinded randomised controlled trial.},
journal = {BMJ open},
year = {2026},
doi = {10.1136/bmjopen-2025-114349},
note = {PMID: 42379722},
}
TY - JOUR AU - Yaqoob A AU - Ladak L AU - Khan AH AU - Almas A AU - Hanif A AU - Pannu FY AU - Khemani F AU - Sahar W AU - Barolia R TI - Effect of home-based cardiac rehabilitation on quality of life, health behaviours and cardiac anxiety in patients with coronary artery disease: findings from a single-blinded randomised controlled trial. T2 - BMJ open PY - 2026 DO - 10.1136/bmjopen-2025-114349 AN - PMID:42379722 ER -
OBJECTIVE: To evaluate the effectiveness of a contextually developed home-based cardiac rehabilitation (HBCR) programme on heart-related quality of life (QoL), cardiac health behaviours (CHB) and cardiac anxiety (CA) among patients with coronary artery disease (CAD) in Lahore, Pakistan. DESIGN: Single-blinded randomised controlled trial (RCT). SETTING: Cardiology department of a public tertiary-care hospital in Lahore, Pakistan. PARTICIPANTS: 120 patients aged 18-65 years diagnosed with coronary artery disease who had undergone percutaneous coronary intervention or medical management were recruited and randomly allocated to intervention (n=60) and control (n=60) groups. INTERVENTION: Participants in the intervention group received a nurse-led HBCR programme consisting of discharge education, structured physical activity and exercise guidance, dietary counselling, medication adherence support, and regular telephonic and physical follow-ups over 24 weeks. The control group received routine care and standard discharge advice. PRIMARY OUTCOME MEASURES: Primary outcomes were heart-related quality of life (MacNew HRQoL), cardiac health behaviours (Cardiac Health Behaviour Scale-21) and cardiac anxiety (Cardiac Anxiety Questionnaire-18), assessed at baseline, 3 months and 6 months postdischarge. RESULTS: At 6-month follow-up, the intervention group demonstrated significantly higher global QoL scores compared with the control group (mean difference 30.71, 95% CI 22.90 to 38.50). CHB scores were also significantly higher in the intervention group (mean difference 19.60, 95% CI 16.20 to 23.00). CA scores were significantly lower among participants receiving HBCR (mean difference -18.72, 95% CI -21.00 to -16.40). These improvements were evident after 3 months and sustained at 6 months. CONCLUSION: The nurse-led HBCR programme significantly improved QoL and CHB and reduced CA among patients with CAD. HBCR may provide an effective and scalable secondary prevention strategy in settings where centre-based cardiac rehabilitation services are limited. TRIAL REGISTRATION: Australian New Zealand Clinical Trial Registry, ACTRN12623000049673p.